Clinical Trial Update: Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

This document provides an update on an open-label extension phase 2 trial of navitoclax in patients with chronic lymphocytic leukemia, noting completion of the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Navitoclax (navitoclax)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED